Associated Papers
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Fischer NW et al.
Nature Communications, 2025
Preferential Sensitivity of the EGFR L858M/L861R Mutation to Second-Generation EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Lee C et al.
Cancer Research and Treatment, 2025
Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics.
Madeddu C et al.
International Journal of Molecular Sciences, 2025
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Computational analysis of protein-protein interactions of cancer drivers in renal cell carcinoma.
Pei J et al.
Febs Open Bio, 2024
DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors.
Folly-Kossi H et al.
Cancer Research Communications, 2023
Li-Fraumeni Syndrome-Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death.
Choe JH et al.
Cancer Discovery, 2023
Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence.
Murali R et al.
Metabolites, 2023
Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.
Marchocki Z et al.
Journal of Ovarian Research, 2022
THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients.
Yao Z et al.
Drug Design, Development and Therapy, 2022
Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability.
Reza MN et al.
Scientific Reports, 2021
Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.
Alvarado-Ortiz E et al.
Frontiers in Cell and Developmental Biology, 2020
TP53 mutations in epithelial ovarian cancer.
Zhang Y et al.
Translational Cancer Research, 2016
Tetramer formation of tumor suppressor protein p53: Structure, function, and applications.
Kamada R et al.
Biopolymers, 2016
Lysines in the tetramerization domain of p53 selectively modulate G1 arrest.
Beckerman R et al.
Cell Cycle (georgetown, Tex.), 2016
Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces.
Engin HB et al.
Plos One, 2016
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Mohell N et al.
Cell Death & Disease, 2015
Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC).
Ricketts CJ et al.
Plos One, 2015
TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Leroy B et al.
Human Mutation, 2014
TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang GN et al.
Gynecologic Oncology, 2014
p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1.
Santiago A et al.
Molecular Biology of the Cell, 2013
The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein.
Muscolini M et al.
The Journal of Biological Chemistry, 2011
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
Ahmed AA et al.
The Journal of Pathology, 2010
Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain.
Muscolini M et al.
Cell Cycle (georgetown, Tex.), 2009
Mutations in the tetramerization domain of p53: more than just keeping monomers apart.
Goldstein I et al.
Cell Cycle (georgetown, Tex.), 2009